Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.61 |
| ▸ | FPR2 | P25090 | 4/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL17202476 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39528 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4969844 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL9903983 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL7127847 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39529 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| SCHEMBL27066372 | 0.99 | FPR1 (0.60) | FPR1FPR2LTA4HMMEMMP2 | |
| SCHEMBL2413701 | 0.99 | FPR1 (0.60) | FPR1FPR2LTA4HMMEMMP2 | |
| SCHEMBL27066369 | 0.94 | FPR1 (0.56) | FPR1FPR2 | |
| SCHEMBL27066397 | 0.94 | FPR1 (0.56) | FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115720-A1 | MEASUREMENT UNIT AND METHOD FOR MANUFACTURING MEASUREMENT UNIT | HAMAMATSU PHOTONICS K.K. (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260086034-A1 | MEASUREMENT DEVICE AND MEASUREMENT METHOD | HAMAMATSU PHOTONICS K.K. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-20250157661-A1 | MONITORING INFLAMMATION STATUS | MOLOGIC LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| US-20240361242-A1 | MEASUREMENT UNIT, METHOD FOR MANUFACTURING MEASUREMENT UNIT, AND BIOLOGICAL SAMPLE MEASUREMENT METHOD | HAMAMATSU PHOTONICS K.K. (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20240287457-A1 | COMPOSITIONS AND CELL CULTURE MEDIA FOR INCREASING NEUTROPHIL LIFESPAN | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-08-29 | — | — | US | disclosed |
| US-11953506-B2 | Monitoring inflammation status | MOLOGIC LIMITED (GB) | 2024-04-09 | — | — | US | disclosed |
| EP-4252850-A2 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | Mereo Biopharma 4 Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-4106757-B1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | MEREO BIOPHARMA 4 LTD (GB) | 2023-08-23 | — | — | EP | disclosed |
| US-20230190723-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | MEREO BIOPHARMA 4 LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| EP-4106757-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | Mereo Biopharma 4 Limited (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-20080317857-A1 | V-Atpase Inhibitors of Use in the Treatment of Septic Shock | BRANE DISCOVERY S.R.L. (IT) | 2008-12-25 | — | — | US | disclosed |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | disclosed |
| EP-1945204-A2 | V-ATPASE INHIBITORS FOR USE IN THE TREATMENT OF SEPTIC SHOCK | BRANE DISCOVERY S.R.L. (IT) | 2008-07-23 | — | — | EP | disclosed |
| EP-1945305-A2 | INDOLE AND AZAINDOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRANE DISCOVERY S.R.L. (IT) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007048847-A2 | INDOLE AND AZAINDOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | NIKEM RESEARCH S.R.L. (IT) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048848-A2 | V-ATPASE INHIBITORS FOR USE IN THE TREATMENT OF SEPTIC SHOCK | BRANE DISCOVERY S.R.L. (IT) | 2007-05-03 | — | — | WO | disclosed |
| EP-1779848-A1 | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases | NIKEM RESEARCH S.R.L. (IT) | 2007-05-02 | — | — | EP | disclosed |
| EP-1779849-A1 | V-ATPase inhibitors for the treatment of septic shock | NIKEM RESEARCH S.R.L. (IT) | 2007-05-02 | — | — | EP | disclosed |
| US-5587457-A | Neutrophil stimulating peptides | PEPTIDE TECHNOLOGY LIMITED (AU) | 1996-12-24 | — | — | US | disclosed |
| EP-0248088-A1 | VASCULARIZATION FACTOR AND PROCESS FOR ITS PREPARATION | TEIJIN LIMITED (JP) | 1987-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260086034-A1 | MEASUREMENT DEVICE AND MEASUREMENT METHOD | SLC18A1, NEFM, NCS1 | FPR1 1048/4885FPR2 1223/4885LTA4H 766/4885 |
| US-20260115720-A1 | MEASUREMENT UNIT AND METHOD FOR MANUFACTURING MEASUREMENT UNIT | UCHL1, NEFM, CYP2U1 | FPR1 3538/4885FPR2 3333/4885LTA4H 622/4885 |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | IDO1, IDO2, INMT | FPR1 157/4885FPR2 310/4885LTA4H 1356/4885 |
| US-20080317857-A1 | V-Atpase Inhibitors of Use in the Treatment of Septic Shock | ATP6V1E1, ATP6V1H, ATP6V1G1 | FPR1 3519/4885FPR2 3476/4885LTA4H 1270/4885 |
| US-20240287457-A1 | COMPOSITIONS AND CELL CULTURE MEDIA FOR INCREASING NEUTROPHIL LIFESPAN | MMP8, NCF1, ELANE | FPR1 15/4885FPR2 20/4885LTA4H 123/4885 |
| US-20230190723-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCY | SERPINB1, ELANE, SERPINA2 | FPR1 48/4885FPR2 209/4885LTA4H 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.